Chemistry:Fulzerasib
From HandWiki
Fulzerasib is a drug that is approved in China to treat KRAS G12C-positive non-small cell lung cancer (NSCLC).[1][2][3]
Prior to marketing approval, fulzerasib had received two breakthrough therapy designations, the first for advanced G12C-mutant NSCLC and a second, for colorectal cancer (CRC) from the Center for Drug Evaluation (CDE) of the Chinese National Medical Products Administration (NMPA).[4]
References
- ↑ "Fulzerasib - GenFleet Therapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800064156.
- ↑ "Fulzerasib: First Approval". Drugs 84 (12): 1665–1671. December 2024. doi:10.1007/s40265-024-02120-6. PMID 39587006.
- ↑ "Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors". Journal of Medicinal Chemistry 68 (15): 15386–15402. August 2025. doi:10.1021/acs.jmedchem.4c03183. PMID 40701936.
- ↑ "Fulzerasib Phase II KROCUS Study | ASCO 2024". DelveInsight Business Research LLP. 2025. https://www.delveinsight.com/asco-conference/article/fulzerasib-phase-ii-krocus-study.
 |  |
